ENOX2

Summary

ENOX2 (ecto-NOX disulfide-thiol exchanger 2, HGNC:2259) is a protein-coding gene on chromosome Xq26.1, encoding Ecto-NOX disulfide-thiol exchanger 2 (Q16206). May be involved in cell growth.

This gene is a tumor-specific member of the ECTO-NOX family of genes that encode cell surface NADH oxidases. The encoded protein has two enzymatic activities: catalysis of hydroquinone or NADH oxidation, and protein disulfide interchange. The protein also displays prion-like properties. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 10495 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 195 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_006375

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2259
Approved symbol	ENOX2
Name	ecto-NOX disulfide-thiol exchanger 2
Location	Xq26.1
Locus type	gene with protein product
Status	Approved
Aliases	APK1, tNOX
Ensembl gene	ENSG00000165675
Ensembl biotype	protein_coding
OMIM	300282
Entrez	10495

Gene structure

Transcript identifiers

Ensembl transcripts: 42 — 41 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000338144, ENST00000370927, ENST00000370935, ENST00000394363, ENST00000432489, ENST00000492263, ENST00000686943, ENST00000714528, ENST00000714529, ENST00000900502, ENST00000900503, ENST00000900504, ENST00000900505, ENST00000900506, ENST00000900507, ENST00000900508, ENST00000900509, ENST00000900510, ENST00000900511, ENST00000900512, ENST00000900513, ENST00000900514, ENST00000900515, ENST00000937154, ENST00000937155, ENST00000937156, ENST00000937157, ENST00000937158, ENST00000937159, ENST00000937160, ENST00000937161, ENST00000937162, ENST00000937163, ENST00000951708, ENST00000951709, ENST00000951710, ENST00000951711, ENST00000951712, ENST00000951713, ENST00000951714, ENST00000951715, ENST00000951716

RefSeq mRNA: 10 — MANE Select: NM_006375 NM_001281736, NM_001382516, NM_001382517, NM_001382518, NM_001382519, NM_001382520, NM_001382521, NM_001382522, NM_006375, NM_182314

CCDS: CCDS14626, CCDS14627, CCDS94664

Canonical transcript exons

ENST00000394363 — 15 exons

Exon	Start	End
ENSE00000676734	130667530	130667742
ENSE00000676735	130669965	130670198
ENSE00000841495	130679542	130679748
ENSE00000979408	130637229	130637410
ENSE00000979409	130634984	130635091
ENSE00000979410	130631468	130631576
ENSE00000979411	130627958	130628043
ENSE00001311339	130665643	130665749
ENSE00001344059	130901684	130901731
ENSE00002715532	130783547	130783690
ENSE00003579849	130688863	130689018
ENSE00003649865	130703120	130703254
ENSE00003751259	130622325	130625445
ENSE00003789622	130656581	130656695
ENSE00003910517	130903049	130903209

Expression profiles

Bgee: expression breadth ubiquitous, 280 present calls, max score 91.05.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.5917 / max 71.0773, expressed in 1776 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200479	6.1877	1714
200480	3.4040	1479

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	91.05	gold quality
tendon	UBERON:0000043	89.68	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.67	gold quality
tendon of biceps brachii	UBERON:0008188	87.55	gold quality
popliteal artery	UBERON:0002250	86.71	gold quality
tibial artery	UBERON:0007610	86.71	gold quality
aorta	UBERON:0000947	85.50	gold quality
right coronary artery	UBERON:0001625	85.39	gold quality
left coronary artery	UBERON:0001626	84.41	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.28	gold quality
thoracic aorta	UBERON:0001515	84.13	gold quality
monocyte	CL:0000576	84.10	gold quality
ascending aorta	UBERON:0001496	84.06	gold quality
islet of Langerhans	UBERON:0000006	83.98	gold quality
stromal cell of endometrium	CL:0002255	83.96	gold quality
mononuclear cell	CL:0000842	83.77	gold quality
leukocyte	CL:0000738	83.68	gold quality
coronary artery	UBERON:0001621	83.45	gold quality
right atrium auricular region	UBERON:0006631	82.66	gold quality
descending thoracic aorta	UBERON:0002345	82.14	gold quality
right adrenal gland cortex	UBERON:0035827	82.14	gold quality
gluteal muscle	UBERON:0002000	82.04	silver quality
right adrenal gland	UBERON:0001233	81.72	gold quality
medial globus pallidus	UBERON:0002477	81.70	gold quality
cardiac atrium	UBERON:0002081	81.38	gold quality
gall bladder	UBERON:0002110	81.30	gold quality
left adrenal gland	UBERON:0001234	81.26	gold quality
heart	UBERON:0000948	81.05	gold quality
heart left ventricle	UBERON:0002084	81.05	gold quality
body of uterus	UBERON:0009853	80.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.62

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

97 targeting ENOX2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-659-3P	99.85	70.69	1620

Literature-anchored findings (GeneRIF, showing 15)

• tNOX is both necessary and sufficient for the cellular anticancer activities attributed to both EGCg and capsaicin. *tNOX enzyme (PMID:15706060)
• results indicate that shRNA targeting of tNOX inhibits the growth of cervical cancer cells, and reduces cell migration via a decrease in the membrane association of Rac. (PMID:18023414)
• A relationship of tNOX to unregulated growth of cancer cells was provided by data where growth of HeLa cells was inhibited by transfection with the exon 5 antisense oligonucleotides (PMID:18351130)
• These results indicate that tNOX is suppressed during apoptosis and demonstrate that tNOX down-regulation sensitizes cells to stress-induced growth reduction, suggesting that tNOX is required for transformed cell growth. (PMID:18789934)
• Enhanced arNOX activity correlates with age and with oxidative changes contributing to skin aging. (PMID:19734125)
• arNOX activity correlates with age and reaches a maximum at about age 65 in males and 55 in females. (PMID:20345278)
• ENOX2 is a dimeric protein containing 4 coppers/dimer capable of carrying out concerted four electron transfers from NADH or ubiquinol to molecular oxygen as required to form water. (PMID:20922471)
• increased NADH levels resulting from ENOX2 inhibition result in decreased prosurvival sphingosine-1-phosphate and increased proapoptotic ceramide, both of which may be important to initiation of the ENOX2 inhibitor-induced apoptotic cascade. (PMID:21571040)
• this result suggests that hnRNP F directs formation of the exon 4 minus variant of ENOX2. (PMID:21625959)
• The results suggest that phosphorylation of serine-504 by PKCdelta modulates the biological function of tNOX. (PMID:22659163)
• The findings support a role for arNOX as a major source of oxidative damage leading to cross-linking of skin proteins. (PMID:24906676)
• These findings not only shed light on the molecular mechanism of the anticancer properties of capsaicin, but also the transcription regulation of tNOX expression that may potentially explain how POU3F2 is associated with tumorigenesis. (PMID:27271588)
• The tumor-associated NADH oxidase (tNOX)-mediated modulation of the NAD+ concentration and SIRT1 are involved in oxaliplatin-induced apoptosis. (PMID:28122359)
• ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia. (PMID:37026766)
• ENOX2 inhibition enhances infiltration of effector memory T-cell and mediates response to chemotherapy in immune-quiescent nasopharyngeal carcinoma. (PMID:37061217)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Enox2	ENSMUSG00000031109
rattus_norvegicus	Enox2	ENSRNOG00000030622
drosophila_melanogaster	CG10948	FBGN0036317

Paralogs (1): ENOX1 (ENSG00000120658)

Protein

Protein identifiers

Ecto-NOX disulfide-thiol exchanger 2 — Q16206 (reviewed: Q16206)

Alternative names: APK1 antigen, Cytosolic ovarian carcinoma antigen 1, Tumor-associated hydroquinone oxidase

All UniProt accessions (5): A0A8I5KRI1, A0AAQ5BI24, A0AAQ5BI25, Q16206, B1AKF7

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in cell growth. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock.

Subcellular location. Cell membrane. Secreted. Extracellular space.

Tissue specificity. Found in the sera of cancer patients with a wide variety of cancers including breast, prostate, lung and ovarian cancers, leukemias, and lymphomas. Not found in the serum of healthy volunteers or patients with disorders other than cancer. Probably shed into serum by cancer cells. Found on the cell borders of renal, kidney and ovarian carcinomas but not on the borders of surrounding non-cancerous stromal cells.

Post-translational modifications. Glycosylated.

Activity regulation. Inhibited by the antitumor sulfonylurea LY181984, the vabilloid capsaicin, and retinoids.

Miscellaneous. Has several properties associated with prions including resistance to proteases, resistance to cyanogen bromide digestion, and the ability to form amyloid filaments resembling those of spongiform encephalopathies.

Similarity. Belongs to the ENOX family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q16206-1	1	yes
Q16206-2	2

RefSeq proteins (10): NP_001268665, NP_001369445, NP_001369446, NP_001369447, NP_001369448, NP_001369449, NP_001369450, NP_001369451, NP_006366, NP_872114 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034140	ENOX_RRM	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR038876	ENOX1/2	Family
IPR056611	ENOX1/2_dom	Domain

Pfam: PF00076, PF23267

UniProt features (23 total): mutagenesis site 10, sequence conflict 6, coiled-coil region 2, sequence variant 2, chain 1, domain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16206-F1	77.86	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (10):

Position	Phenotype
546	loss of activity.
558	period length of activity extended to 42 minutes.
562	loss of activity.
569	loss of activity.
575	period length of activity extended to 36 minutes.
592	loss of activity.
602	period length of activity extended to 36 minutes.
396	no effect on activity but response to capsaicin is lost.
505	no effect on activity.
510	loss of activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 126 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOCC_CELL_SURFACE, AACYNNNNTTCCS_UNKNOWN, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, MARTINEZ_RB1_TARGETS_DN, BRN2_01, MORF_IL4, GOBP_ELECTRON_TRANSPORT_CHAIN, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, SHEN_SMARCA2_TARGETS_DN, GOCC_SIDE_OF_MEMBRANE, SMITH_TERT_TARGETS_UP, STAT1_02

GO Biological Process (3): ultradian rhythm (GO:0007624), electron transport chain (GO:0022900), rhythmic process (GO:0048511)

GO Molecular Function (4): RNA binding (GO:0003723), oxidoreductase activity (GO:0016491), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (5): extracellular region (GO:0005576), cytosol (GO:0005829), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
binding	2
rhythmic process	1
generation of precursor metabolites and energy	1
biological_process	1
nucleic acid binding	1
catalytic activity	1
cytoplasm	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1

Protein interactions and networks

STRING

654 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ENOX2	ACE2	Q9BYF1	680
ENOX2	DIPK2A	Q8NDZ4	440
ENOX2	ZNF638	Q14966	408
ENOX2	R3HCC1	Q9Y3T6	389
ENOX2	CDR2	Q01850	356
ENOX2	CLASP1	Q7Z460	355
ENOX2	RASD2	Q96D21	348
ENOX2	ALDH18A1	P54886	348
ENOX2	UFM1	P61960	348
ENOX2	FNDC5	Q8NAU1	346
ENOX2	BNC2	Q6ZN30	337
ENOX2	YPEL1	O60688	333
ENOX2	C1QL4	Q86Z23	332
ENOX2	UBE2G2	P56554	322
ENOX2	TTC1	Q99614	314

IntAct

17 interactions, top by confidence:

A	B	Type	Score
RPP25L	RPP40	psi-mi:“MI:0914”(association)	0.530
RPP30	RPP40	psi-mi:“MI:0914”(association)	0.530
ENOX2	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
ENOX2		psi-mi:“MI:0915”(physical association)	0.370
ENOX2	TK	psi-mi:“MI:0915”(physical association)	0.370
	ENOX2	psi-mi:“MI:0915”(physical association)	0.370
TUBB4B	ENOX2	psi-mi:“MI:0915”(physical association)	0.370
MAGEA11	ENOX2	psi-mi:“MI:0915”(physical association)	0.370
ENOX2	ENOX1	psi-mi:“MI:0915”(physical association)	0.370
SOX2	CBX4	psi-mi:“MI:0914”(association)	0.350
SRSF4		psi-mi:“MI:0914”(association)	0.350
SRSF5	FBLL1	psi-mi:“MI:0914”(association)	0.350
POP5	RPP40	psi-mi:“MI:0914”(association)	0.350
SRSF5	GTPBP10	psi-mi:“MI:0914”(association)	0.350
POP5	TPP1	psi-mi:“MI:0914”(association)	0.350
E2F3	MYO1C	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): ENOX2 (Two-hybrid), ENOX2 (Two-hybrid), ENOX2 (Two-hybrid), ENOX2 (Two-hybrid), ENOX1 (Two-hybrid), CIB3 (Two-hybrid), ENOX2 (Affinity Capture-RNA), ENOX2 (Affinity Capture-RNA), ENOX2 (Affinity Capture-MS), ENOX2 (Two-hybrid), ENOX1 (Two-hybrid), ENOX2 (Two-hybrid), ENOX2 (Affinity Capture-RNA), ENOX2 (Affinity Capture-RNA), ENOX2 (Two-hybrid)

ESM2 similar proteins: A0JMA8, A0MZ66, A0MZ67, A1A5P5, A4IGC3, A5WW21, B3DLE8, H2MTR9, P70302, P84903, Q08DR9, Q0P4J3, Q13586, Q16206, Q28IH8, Q2TAA8, Q3KR99, Q4R6I5, Q5BIX7, Q5I033, Q5M8Y7, Q5RA03, Q5U245, Q5XG48, Q5XIR8, Q6GP65, Q6IP02, Q6IQY5, Q6NRK1, Q6NRW2, Q6NRX3, Q6P0R8, Q6P402, Q7T0S7, Q7Z3E5, Q8BXX9, Q8K2Q9, Q8K4I6, Q8MJK1, Q8N6V9

Diamond homologs: A6NDY0, B0BNE4, B1WC40, B7P877, O13741, O14327, O75494, O89086, O93235, P07909, P40561, P41891, P42696, P48810, P52298, P53883, P98179, Q00916, Q02926, Q08208, Q09295, Q09301, Q15056, Q16206, Q177H0, Q1HE01, Q1JPH6, Q28165, Q28ZX3, Q3MHY8, Q3ZBJ1, Q499V6, Q54ZS8, Q56JZ7, Q5M9F1, Q5RBR8, Q5XFR0, Q5XI72, Q6C2Q7, Q6CKV6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PRKCD	up-regulates	ENOX2	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

195 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	60
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
564897	GRCh37/hg19 Xq25-28(chrX:125733292-155233846)x1	Pathogenic

SpliceAI

4399 predictions. Top by Δscore:

Variant	Effect	Δscore
X:130634979:TGTA:T	donor_loss	1.0000
X:130634980:GTAC:G	donor_loss	1.0000
X:130634981:TA:T	donor_loss	1.0000
X:130634983:C:T	donor_loss	1.0000
X:130635087:AGATG:A	acceptor_gain	1.0000
X:130635088:GATG:G	acceptor_gain	1.0000
X:130635089:ATG:A	acceptor_gain	1.0000
X:130635090:TG:T	acceptor_gain	1.0000
X:130635091:GCT:G	acceptor_loss	1.0000
X:130635092:C:CC	acceptor_gain	1.0000
X:130635092:CTA:C	acceptor_loss	1.0000
X:130635093:T:C	acceptor_loss	1.0000
X:130637223:CTTTA:C	donor_loss	1.0000
X:130637224:TTTA:T	donor_loss	1.0000
X:130637225:TTACC:T	donor_loss	1.0000
X:130637226:TAC:T	donor_loss	1.0000
X:130637227:A:AT	donor_loss	1.0000
X:130637228:C:A	donor_loss	1.0000
X:130665639:CAA:C	donor_loss	1.0000
X:130665640:AAC:A	donor_loss	1.0000
X:130665641:A:AG	donor_loss	1.0000
X:130665642:C:CA	donor_loss	1.0000
X:130665647:G:C	donor_gain	1.0000
X:130665781:CAGGG:C	acceptor_gain	1.0000
X:130665789:C:CT	acceptor_gain	1.0000
X:130665793:C:CT	acceptor_gain	1.0000
X:130665793:C:T	acceptor_gain	1.0000
X:130665794:A:T	acceptor_gain	1.0000
X:130665798:A:AC	acceptor_gain	1.0000
X:130665798:A:C	acceptor_gain	1.0000

AlphaMissense

3876 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:130625352:A:G	W599R	1.000
X:130625352:A:T	W599R	1.000
X:130625372:C:T	G592E	1.000
X:130625373:C:G	G592R	1.000
X:130625373:C:T	G592R	1.000
X:130625378:C:T	G590E	1.000
X:130625396:A:G	F584S	1.000
X:130627981:A:C	Y560D	1.000
X:130627993:A:G	Y556H	1.000
X:130628007:C:A	G551V	1.000
X:130628007:C:T	G551E	1.000
X:130628008:C:G	G551R	1.000
X:130628008:C:T	G551R	1.000
X:130628015:G:C	H548Q	1.000
X:130628015:G:T	H548Q	1.000
X:130628017:G:C	H548D	1.000
X:130628025:A:G	L545P	1.000
X:130628027:G:C	F544L	1.000
X:130628027:G:T	F544L	1.000
X:130628028:A:G	F544S	1.000
X:130628029:A:G	F544L	1.000
X:130665648:C:G	A366P	1.000
X:130665660:A:G	W362R	1.000
X:130665660:A:T	W362R	1.000
X:130665673:C:A	K357N	1.000
X:130665673:C:G	K357N	1.000
X:130665675:T:C	K357E	1.000
X:130665677:C:G	R356P	1.000
X:130665679:C:A	Q355H	1.000
X:130665679:C:G	Q355H	1.000

dbSNP variants (sampled 300 via entrez): RS1000002290 (X:130691534 T>C), RS1000009448 (X:130764061 A>G), RS1000014659 (X:130679344 C>A), RS1000086418 (X:130743547 T>C), RS1000128096 (X:130873560 T>C), RS1000129910 (X:130807380 G>A), RS1000152572 (X:130757781 T>C), RS1000166531 (X:130718997 C>T), RS1000172840 (X:130758024 T>C), RS1000174869 (X:130819281 T>G), RS1000185505 (X:130902162 C>G), RS1000195403 (X:130901727 G>C,T), RS1000197455 (X:130623070 C>T), RS1000222832 (X:130769189 T>C), RS1000259650 (X:130737973 C>T)

Disease associations

OMIM: gene MIM:300282 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002384_518	Hemoglobin	7.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004509	hemoglobin measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3714292 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	6
epigallocatechin gallate	increases response to substance, decreases activity, increases abundance	2
Vehicle Emissions	increases expression, decreases expression, increases abundance, decreases reaction	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression, decreases expression	2
Aflatoxin B1	decreases expression, decreases methylation	2
Particulate Matter	decreases reaction, increases expression, decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
phenoxodiol	decreases activity, increases abundance	1
abrine	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
bisphenol S	affects cotreatment, decreases methylation	1
Arsenic Trioxide	increases expression	1
Fulvestrant	decreases methylation, affects cotreatment, increases methylation	1
Asbestos	affects response to substance	1
Capsaicin	increases response to substance	1
Carbamazepine	affects expression	1
Doxorubicin	decreases expression	1
Endosulfan	increases expression	1
NAD	decreases activity, increases abundance	1
Polychlorinated Biphenyls	affects expression	1
Valproic Acid	decreases methylation	1
Lithium Chloride	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3748910	Binding	Inhibition of tNOX in human AGS cells assessed as reduction in cell migration	Synthesis and Characterization of 4,11-Diaminoanthra[2,3-b]furan-5,10-diones: Tumor Cell Apoptosis through tNOX-Modulated NAD(+)/NADH Ratio and SIRT1. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.